Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lubiprostone in Opioid-induced Bowel Dysfunction
NCT01298219Phase 3Completed
- Sponsor
- Sucampo
- Start
- Dec 2010
- Primary completion
- Nov 2011
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced bowel dysfunction (OIBD) comparing Lubiprostone with Placebo (2 arms). Primary endpoint: Number of Participants Classified as Treatment Responders at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
cobiprostone
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT01298219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298219.